

ATTORNEY DOCKET NO.: 2003946-0055

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Takeuchi, et al. Examiner:  
Serial No.: 10/645,335 Art Unit:  
Filing Date: August 21, 2003  
Title: RABCONNECTIN-3-BINDING PROTEIN

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


**TRANSMITTAL LETTER**

Enclosed are the following documents:

1. Form PTO-1449 (2 pages);
2. Information Disclosure Statement (6 pages);
3. Cited Art (16 documents);
4. Statement of Limited Recognition (1 page); and
5. Return Postcard

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,

  
\_\_\_\_\_  
Charles E. Lyon, D.Phil.

Agent for Applicant

Limited Recognition Under 37 CFR §10.9(b)

Choate, Hall & Stewart  
Exchange Place  
53 State Street  
Boston, MA 02109  
(617) 248-5000

Dated: December 18, 2003

3636484\_1.DOC

**Certificate of Mailing**

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

12-18-03   
Date Signature

Sandra Saccoccia

Typed or Printed Name of person signing certificate



ATTORNEY DOCKET NO.: 2003946-0055

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Takeuchi, et al. Examiner:  
Serial No.: 10/645,335 Art Unit:  
Filing Date: August 21, 2003  
Title: RABCONNECTIN-3-BINDING PROTEIN

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

- ☒ An *original* Information Disclosure Statement; or  
☐ A *supplemental* Information Disclosure Statement.

<b>Certificate of Mailing</b>	
I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
12-18-03	<i>Sandra Saccocia</i>
Date	Signature
Sandra Saccocia	
Typed or Printed Name of person signing certificate	

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

- ☒ Pursuant to 37 CFR § 1.97(b); no fee or certification is required:
  - ☐ Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
  - ☐ Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
  - ☒ Before the mailing of a first Office action on the merits; or
  - ☐ Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- ☐ Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:
  - ☐ Certifies that *either*:
    - ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
    - ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making

reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; or

☐ Includes herewith the fee set forth in § 1.17(p).

☐ Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:

☐ Certifies that *either*:

☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; and

☐ Includes herewith the fee set forth in § 1.17(p).

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- ☒ A copy of each cited reference not indicated with an asterisk is included;
- ☐ Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

- ☐ Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

- ☐ Does not contain non-English language citations;
- ☐ Does contain non-English language citations, of which the following is a concise explanation:
- ☐ Includes one or more translations of a non-English citation.

## Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .


The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,

  
\_\_\_\_\_  
Charles E. Lyon, D.Phil.  
Agent for Applicant  
Limited Recognition Under 37 CFR §10.9(b)

CHOATE, HALL & STEWART  
Exchange Place  
53 State Street  
Boston, Massachusetts 02109  
(617) 248-5000  
(617) 248-4000

Dated: December 18, 2003

3635858

Form PTO-1449 (REV. 8-83) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Atty. Docket: 2003946-0055		In re Application No. 10/645,335	
		Applicant: Takeuchi, <i>et al.</i>			
		Filing Date: August 21, 2003		Group:	

<b>U.S. PATENT DOCUMENTS</b>					
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass

<b>U.S. PATENT APPLICATIONS</b>					
Examiner's Initials	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No
	EP 0 856 583	Europe	05 August 1998		
	JP 2001-309733	Japan	06 November 2001		
	JP 10-276783	Japan	20 October 1998		

<b>OTHER DOCUMENTS</b>	
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)
	GenBank Accession No. AB011113
	GenBank Accession No. AC007052
	GenBank Accession No. AC008006
	GenBank Accession No. AF305813
	GenBank Accession No. XM028588
	Nagano, et al., "Molecular Cloning and Characterization of the Noncatalytic Subunit of the Rab3 Subfamily-Specific GTPase-Activating Protein", <i>The Journal of Biological Chemistry</i> , 273(38): 24781-74785, 1998.
	Nagano, et al., "Rabconnectin-3, a Novel Protein that Binds Both GDP/GTP Exchange Protein and GTPase-Activating Protein for Rab3 Small G Protein Family", <i>The Journal of Biological Chemistry</i> , 277(12): 9629-9632, 2002.
	Nakanishi, et al., "Isolation of Regulatory Proteins for the Rab3 Subfamily GTPases", <i>Methods in Molecular Biology</i> , 189: 143-157.
	Oishi, et al., "Localization of the Rab3 Small G Protein Regulators in Nerve Terminals and Their Involvement in Ca <sup>2+</sup> - Dependent Exocytosis", <i>The Journal of Biological Chemistry</i> , 273(51): 34580-34585, 1998.
	Sanders, et al., "Assignment of WDR7 (Alias TRAG, TGF-β Resistance Associated Gene) to Orthologous Regions of Human Chromosome 18q21.1→q22 and Mouse Chromosome 18D.1-E.3 by Fluorescence in Situ Hybridization", <i>Cytogenet Cell Genet</i> , 88: 324-325, 2000.



<b>Form PTO-1449</b> <b>(REV. 8-83)</b>		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2003946-0055	In re Application No. 10/645,335
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)			Applicant: Takeuchi, <i>et al.</i>	
			Filing Date: August 21, 2003	Group:
<b>OTHER DOCUMENTS</b>				
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)			
	Tanaka, et al., "Role of Rab3 GDP/GTP Exchange Protein in Synaptic Vesicle Trafficking at the Mouse Neuromuscular Junction", <i>Molecular Biology of the Cell</i> , <b>12</b> : 1421-1430, 2001.			
	Wada, et al., "Isolation and Characterization of A GDP/GTP Exchange Protein Specific for the Rab3 Subfamily Small G Proteins", <i>The Journal of Biological Chemistry</i> , <b>272</b> (7): 3875-3878, 1997.			
	Yamaguchi, et al., "A GDP/GTP Exchange Protein for the Rab3 Small G Protein Family Up-Regulates a Postdocking Step of Synaptic Exocytosis in Central Synapses", <i>PNAS</i> , <b>99</b> (22): 14536-14541, 2002.			
EXAMINER			DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

3630134